Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).

NCT05010876 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Covid19

Interventions

DRUG: C1 Inhibitor Human
DRUG: Icatibant Injection
OTHER: Placebo

Sponsor

GCS Ramsay Santé pour l'Enseignement et la Recherche